Pharmacological inhibition of sympathetic nerve activity to achieve sustained weight loss and improvements in insulin sensitivity, glucose tolerance, dyslipidemia, and hypertension is currently under intense investigation. This evidence concerns the gene INS and metabolic syndrome.